#1 Clinical Trials Search in Europe

Resiquimod Sulfate

Resiquimod Sulfate, also known as EIK1001 or BDB001, is an investigational drug being studied in clinical trials for the treatment of advanced solid tumors and melanoma. This article will explore the ongoing research on Resiquimod Sulfate, its potential benefits, and its role in combination with other cancer treatments.

Table of Contents

What is RESIQUIMOD SULFATE?

RESIQUIMOD SULFATE is an investigational drug being studied for its potential in treating various advanced solid tumors and melanoma. It is also known by its product names EIK1001 and BDB001[1][2]. This medication is currently undergoing clinical trials to evaluate its safety and efficacy in combination with other cancer treatments.

How does it work?

RESIQUIMOD SULFATE is a Toll-like receptor (TLR) 7/8 agonist[1]. TLRs are a type of protein that plays a crucial role in the immune system. By activating TLR 7 and 8, RESIQUIMOD SULFATE may help stimulate the body’s immune response against cancer cells. This mechanism of action makes it a potential candidate for immunotherapy, a type of cancer treatment that harnesses the power of the body’s own immune system to fight cancer.

What conditions does RESIQUIMOD SULFATE treat?

RESIQUIMOD SULFATE is being investigated for the treatment of several types of advanced solid tumors and melanoma. The ongoing clinical trials are focusing on the following conditions:

  • Advanced solid tumors, including:
    • Pancreatic cancer
    • Virus-associated tumors (such as HPV-related cancers, Epstein-Barr virus-associated cancers, and Kaposi’s sarcoma)
    • Non-small cell lung cancer
    • Soft-tissue sarcomas
    • Bladder cancer
    • Triple-negative breast cancer
  • Advanced melanoma (Stage 3 unresectable or Stage 4 metastatic)[1][2]

Current Clinical Trials

There are currently two notable clinical trials investigating RESIQUIMOD SULFATE:

  1. AGADIR Study: This trial is evaluating the combination of RESIQUIMOD SULFATE (EIK1001/BDB001) with atezolizumab and radiotherapy in patients with advanced solid tumors[1].
  2. Advanced Melanoma Study: This is a multicenter, randomized, double-blind study comparing RESIQUIMOD SULFATE (EIK1001) in combination with pembrolizumab versus placebo and pembrolizumab as a first-line therapy for patients with advanced melanoma[2].

These trials aim to assess the safety and efficacy of RESIQUIMOD SULFATE in combination with other cancer treatments, particularly immunotherapy drugs like atezolizumab and pembrolizumab.

How is RESIQUIMOD SULFATE administered?

RESIQUIMOD SULFATE is administered as a solution for injection. In the clinical trials, it is being given through intravenous infusion[1][2]. The exact dosage and frequency of administration may vary depending on the specific trial and the patient’s condition. It’s important to note that as an investigational drug, the optimal dosing regimen is still being determined through these clinical studies.

Potential Side Effects

As RESIQUIMOD SULFATE is still in the investigational stage, the full range of potential side effects is not yet known. The ongoing clinical trials are designed to evaluate the safety profile of this medication, particularly when used in combination with other cancer treatments.

Patients participating in these trials will be closely monitored for any adverse events. Some general side effects that may be associated with immunotherapy drugs include:

  • Fatigue
  • Skin reactions
  • Gastrointestinal issues (nausea, diarrhea)
  • Flu-like symptoms
  • Potential immune-related side effects

It’s important to remember that the occurrence and severity of side effects can vary from person to person. Patients should always discuss potential risks and benefits with their healthcare provider.

Conclusion

RESIQUIMOD SULFATE (EIK1001/BDB001) is a promising investigational drug that may offer new hope for patients with advanced solid tumors and melanoma. By stimulating the immune system through TLR 7/8 activation, it has the potential to enhance the body’s ability to fight cancer cells. The ongoing clinical trials will provide valuable information about its efficacy and safety, particularly when used in combination with other cancer treatments.

As research continues, RESIQUIMOD SULFATE may become an important addition to the arsenal of cancer treatments, potentially improving outcomes for patients with difficult-to-treat cancers. However, it’s crucial to remember that as an investigational drug, it is not yet approved for general use, and more studies are needed to fully understand its benefits and risks.

Aspect Details
Drug Name Resiquimod Sulfate (EIK1001, BDB001)
Drug Class Toll-like receptor (TLR) agonist
Administration Intravenous infusion or injection
Cancer Types Studied Advanced solid tumors (including pancreatic, virus-associated, non-small cell lung, soft-tissue sarcomas, bladder, triple-negative breast) and advanced melanoma
Combination Therapies Atezolizumab and radiotherapy (for solid tumors), Pembrolizumab (for melanoma)
Primary Objectives Evaluate antitumor activity, progression-free survival, overall survival
Secondary Objectives Assess safety, objective response rate, duration of response
Trial Phases Phase 2/3
Key Measurements RECIST criteria, iRECIST, Growth Modulation Index

FAQ

  • What is Resiquimod Sulfate? Resiquimod Sulfate, also known as EIK1001 or BDB001, is an investigational drug being studied for the treatment of advanced solid tumors and melanoma. It belongs to a class of drugs called Toll-like receptor (TLR) agonists, which work by stimulating the immune system to fight cancer cells.
  • How is Resiquimod Sulfate administered? Resiquimod Sulfate is administered as an intravenous infusion or injection. The exact dosage and frequency may vary depending on the specific clinical trial and the patient's condition.
  • What types of cancer is Resiquimod Sulfate being studied for? Resiquimod Sulfate is being studied for various types of advanced solid tumors, including pancreatic cancer, virus-associated tumors, non-small cell lung cancer, soft-tissue sarcomas, bladder cancer, triple-negative breast cancer, and advanced melanoma.
  • Is Resiquimod Sulfate used alone or in combination with other treatments? In the clinical trials discussed, Resiquimod Sulfate is being studied in combination with other treatments. For example, it is being combined with atezolizumab and radiotherapy for advanced solid tumors, and with pembrolizumab for advanced melanoma.
  • What are the potential side effects of Resiquimod Sulfate? As Resiquimod Sulfate is still in clinical trials, the full range of potential side effects is not yet known. The trials are designed to evaluate the safety and tolerability of the drug. Patients in the trials are closely monitored for any adverse events.

Ongoing Clinical Trials on Resiquimod Sulfate

  • Study on Atezolizumab and Resiquimod Sulfate with Radiotherapy for Patients with Advanced Solid Tumors

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

    Recruiting

    4 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Finland +9

  • EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

    Not yet recruiting

    2 1 1
    Investigated drugs:
    Germany Greece Italy The Netherlands Romania Spain

Glossary

  • Atezolizumab: A type of immunotherapy drug used to treat certain types of cancer by helping the immune system recognize and attack cancer cells.
  • BICR: Blinded Independent Central Review, a method used to assess treatment outcomes in clinical trials without bias.
  • BRAF V600 mutation: A specific change in the BRAF gene that can be found in some melanomas and other cancers, which may affect treatment choices.
  • CTCAE: Common Terminology Criteria for Adverse Events, a standardized system for describing and grading the severity of side effects in cancer therapy clinical trials.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Growth Modulation Index (GMI): A measure used to evaluate the effectiveness of a cancer treatment by comparing the progression-free survival of a patient on the new treatment to their progression-free survival on their previous treatment.
  • iRECIST: Immune Response Evaluation Criteria In Solid Tumors, a set of rules used to assess how well a cancer treatment is working, specifically designed for immunotherapy treatments.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Pembrolizumab: An immunotherapy drug used to treat various types of cancer by helping the immune system recognize and fight cancer cells.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Resiquimod Sulfate: An investigational drug (also known as EIK1001 or BDB001) being studied for its potential to stimulate the immune system to fight cancer cells.
  • Toll-like receptor (TLR) agonist: A type of drug that activates specific receptors in the immune system, potentially enhancing the body's ability to fight cancer.

References

  1. http://clinicaltrials.eu/trial/study-on-atezolizumab-and-resiquimod-sulfate-with-radiotherapy-for-patients-with-advanced-solid-tumors/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-eik1001-and-pembrolizumab-for-patients-with-advanced-melanoma/